Intensity Therapeutics, Inc. (INTS)
NASDAQ: INTS · Real-Time Price · USD
0.2820
-0.0090 (-3.09%)
At close: Aug 29, 2025, 4:00 PM
0.2900
+0.0080 (2.84%)
Pre-market: Sep 2, 2025, 6:35 AM EDT
Company Description
Intensity Therapeutics, Inc., a late-stage clinical biotechnology company, engages in the provision of treatment for the regional and systemic nature of cancer in the United States.
Its lead product candidate includes INT230-6, which is in Phase 3 clinical studies for the treatment of soft tissue sarcoma; and neoadjuvant and metastatic triple negative breast cancer which is in Phase 2 clinical trials.
The company was incorporated in 2012 and is headquartered in Shelton, Connecticut.
Intensity Therapeutics, Inc.
| Country | United States |
| Founded | 2012 |
| IPO Date | Jun 30, 2023 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 7 |
| CEO | Lewis Bender |
Contact Details
Address: 1 Enterprise Drive, Suite 430 Shelton, Connecticut 06484-4779 United States | |
| Phone | 203 221 7381 |
| Website | intensitytherapeutics.com |
Stock Details
| Ticker Symbol | INTS |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $5.00 |
| CIK Code | 0001567264 |
| CUSIP Number | 45812M104 |
| ISIN Number | US45828J1034 |
| Employer ID | 46-1488089 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Lewis H. Bender M.A., M.B.A., M.S. | Founder, President, Chief Executive Officer and Chairman of the Board |
| Joseph Talamo CPA, M.B.A. | Chief Financial Officer |
| James M. Ahlers | Executive Vice President of Corporate Finance |
| Brian Schwartz M.D. | Executive Vice President of Clinical Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 28, 2025 | PRE 14A | Other preliminary proxy statements |
| Aug 14, 2025 | SCHEDULE 13G/A | Filing |
| Aug 12, 2025 | 8-K | Current Report |
| Aug 7, 2025 | 8-K | Current Report |
| Aug 7, 2025 | 10-Q | Quarterly Report |
| Aug 4, 2025 | 8-K | Current Report |
| Jul 18, 2025 | 8-K | Current Report |
| Jul 9, 2025 | SCHEDULE 13G/A | Filing |
| Jun 27, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
| Jun 18, 2025 | 424B5 | Filing |